Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
Exploiting GLIOMATCH results for clinical development
Results generated within the GLIOMATCH project are contributing to the advancement of innovative therapeutic strategies for glioblastoma.
The newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics together with GLIOMATCH partner LISCO – KU Leuven Institute for Single Cell Omics, builds directly on findings obtained within GLIOMATCH.
GLIOBREAK will advance BEA-17, a first-in-class LSD1–CoREST degrader, alongside the development of a companion diagnostic. The project aims to bring the programme to clinical readiness, including the completion of IND-enabling studies and preparation for regulatory submission.
The consortium has secured EUR 2.5 million in funding from the European Innovation Council to support these next steps towards clinical development.
Read the full press release here.